James W. Smithy, MD, MHS, discusses the key findings from a phase 2 trial of IO102-IO103 plus nivolumab/relatlimab in advanced melanoma.
James W. Smithy, MD, MHS
Advertisement
James W. Smithy, MD, MHS is Assistant Attending Physician and
Vice Chair, Quality Assessment, Cellular Therapy Service at Memorial Sloan Kettering Cancer Center.
Articles by James W. Smithy, MD, MHS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
CMS Proposes Cut to 340B Drug Payments in 2027 Outpatient Rule
2
After the First TKI Fails: Sequencing Challenges in ROS1-Positive NSCLC
3
Further MonumenTAL-3 Follow-Up Needed for Triplet Regimen in Relapsed Myeloma
4
Adagrasib Plus Cetuximab Falls Short in KRAS G12C–Mutated Colorectal Cancer
5